Enabling EarlierDetection andSmarter Follow-Up with AI.
Qure.ai is enabling a paradigm shift in thoracic oncology - from reactive diagnosis to proactive, AI-powered detection and longitudinal follow-up. By translating routine chest imaging into actionable insights, we help clinicians and life sciences partners catch lung cancer earlier, manage nodules more consistently, and move patients into the right care pathway faster.
Meet the Qure team at WCLC 2026 | Booth #329
Beyond Detection: AI for End-to-End Lung Cancer Care
AI-derived imaging biomarkers help identify patients at risk of lung cancer earlier - including incidental and previously missed nodules on routine chest radiographs - supporting earlier-stage diagnosis and faster entry into treatment pathways.
Beyond detection, AI supports longitudinal tracking of pulmonary nodules over time - helping ensure consistent, guideline-aligned follow-up and reducing patients lost to follow-up between scans.
Agentic AI capabilities help identify and surface potential patient cohorts for lung cancer trials, enabling life sciences teams to explore faster recruitment and program readiness.
Multicenter validation studies - from University Hospitals Cleveland to spirometry-paired vision-language model research - demonstrate consistent real-world performance, supporting guideline-concordant adoption across geographies.
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Ex-Vice President, International Oncology
AstraZeneca
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
